| Title | Endocrine, Metabolic and Immune Disorders - Drug Targets |
| Abbreviation | Endocr. Metab. Immune Disord. - Drug Targets |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Endocrinology, Diabetes and Metabolism (Q3); Immunology and Allergy (Q3) |
| h-index | 66 |
| Overall Rank/Ranking | 10854 |
| SCImago Journal Rank (SJR) | 0.535 |
| Impact Score | 2.03 |
| Publisher | Bentham Science Publishers |
| Country | United Arab Emirates |
| ISSN | 22123873, 18715303 |
| Best Quartile | Q3 |
| Coverage History | 2006-2025 |
Endocrine, Metabolic and Immune Disorders - Drug Targets is a journal covering the technologies/fields/categories related to Endocrinology, Diabetes and Metabolism (Q3); Immunology and Allergy (Q3). It is published by Bentham Science Publishers. The overall rank of Endocrine, Metabolic and Immune Disorders - Drug Targets is 10854. According to SCImago Journal Rank (SJR), this journal is ranked 0.535. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 66. The best quartile for this journal is Q3.
The ISSN of Endocrine, Metabolic and Immune Disorders - Drug Targets journal is 22123873, 18715303. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Endocrine, Metabolic and Immune Disorders - Drug Targets is cited by a total of 1191 articles during the last 3 years (Preceding 2024).
The Impact IF 2024 of Endocrine, Metabolic and Immune Disorders - Drug Targets is 2.03, which is computed in 2025 as per its definition. Endocrine, Metabolic and Immune Disorders - Drug Targets IF is decreased by a factor of 0.03 and approximate percentage change is -1.46% when compared to preceding year 2023, which shows a falling trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2024 of Endocrine, Metabolic and Immune Disorders - Drug Targets is 2.03. If the same downward trend persists, Impact IF may fall in 2025 as well.
| Year | Impact IF |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 2.03 |
| 2023 | 2.06 |
| 2022 | 1.97 |
| 2021 | 2.31 |
| 2020 | 2.77 |
| 2019 | 2.03 |
| 2018 | 1.28 |
| 2017 | 1.98 |
| 2016 | 2.17 |
| 2015 | 2.06 |
| 2014 | 1.78 |
Endocrine, Metabolic and Immune Disorders - Drug Targets has an h-index of 66. It means 66 articles of this journal have more than 66 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Endocrine, Metabolic and Immune Disorders - Drug Targets is 22123873, 18715303. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Endocrine, Metabolic and Immune Disorders - Drug Targets is 10854. According to SCImago Journal Rank (SJR), this journal is ranked 0.535. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 0.535 |
| 2023 | 0.495 |
| 2022 | 0.427 |
| 2021 | 0.490 |
| 2020 | 0.518 |
| 2019 | 0.465 |
| 2018 | 0.656 |
| 2017 | 0.742 |
| 2016 | 0.648 |
| 2015 | 0.757 |
| 2014 | 0.679 |
| Year | Ranking |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 10854 |
| 2023 | 10873 |
| 2022 | 11874 |
| 2021 | 10188 |
| 2020 | 9768 |
| 2019 | 10449 |
| 2018 | 7355 |
| 2017 | 6327 |
| 2016 | 7309 |
| 2015 | 6269 |
| 2014 | 6870 |
Endocrine, Metabolic and Immune Disorders - Drug Targets is published by Bentham Science Publishers. It's publishing house is located in United Arab Emirates. Coverage history of this journal is as following: 2006-2025. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Endocrine, Metabolic and Immune Disorders - Drug Targets is Endocr. Metab. Immune Disord. - Drug Targets. This abbreviation ('Endocr. Metab. Immune Disord. - Drug Targets') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Endocrinology, Diabetes and Metabolism (Q3); Immunology and Allergy (Q3), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Endocrine, Metabolic and Immune Disorders - Drug Targets latest impact IF is 2.03. It's evaluated in the year 2024. The highest and the lowest impact IF or impact score of this journal are 2.77 (2020) and 1.28 (2018), respectively, in the last 11 years. Moreover, its average IS is 2.04 in the previous 11 years.
The Endocrine, Metabolic and Immune Disorders - Drug Targets has an SJR (SCImago Journal Rank) of 0.535, according to the latest data. It is computed in the year 2025. In the past 11 years, this journal has recorded a range of SJR, with the highest being 0.757 in 2015 and the lowest being 0.427 in 2022. Furthermore, the average SJR of the Endocrine, Metabolic and Immune Disorders - Drug Targets over the previous 11-year period stands at 2.04.
The latest h-index of the Endocrine, Metabolic and Immune Disorders - Drug Targets is 66.
The Endocrine, Metabolic and Immune Disorders - Drug Targets is published by the Bentham Science Publishers, with its country of publication being the United Arab Emirates.
The Endocrine, Metabolic and Immune Disorders - Drug Targets is currently ranked 10854 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 11 years, this journal has experienced varying rankings, reaching its highest position of 6269 in 2015 and its lowest position of 11874 in 2022.
The standard ISO4 abbreviation for the Endocrine, Metabolic and Immune Disorders - Drug Targets is Endocr. Metab. Immune Disord. - Drug Targets.
Endocrine, Metabolic and Immune Disorders - Drug Targets is classified as a journal that the Bentham Science Publishers publishes.
The Endocrine, Metabolic and Immune Disorders - Drug Targets encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Endocrine, Metabolic and Immune Disorders - Drug Targets is assigned the following International Standard Serial Numbers (ISSN): 22123873, 18715303.
The best quartile for the Endocrine, Metabolic and Immune Disorders - Drug Targets is Q3 (2024).
The Endocrine, Metabolic and Immune Disorders - Drug Targets coverage history can be summarized as follows: 2006-2025.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Journal of Academic Ethics | journal | 8704 | Springer Netherlands | 34 | 4.04 |
| Business: Theory and Practice | journal | 16073 | Vilnius Gediminas Technical University | 31 | 2.45 |
| Qualitative Research | journal | 1300 | SAGE Publications Ltd | 101 | 6.77 |
| International Journal of Applied Linguistics | journal | 6655 | Wiley-Blackwell Publishing Ltd | 57 | 2.61 |
| World Englishes | journal | 7267 | Wiley-Blackwell | 68 | 2.38 |
| Marine Biology Research | journal | 14618 | Taylor and Francis Ltd. | 47 | 1.21 |
| Proceedings of the International Semiconductor Conference, CAS | conference and proceedings | 25734 | Institute of Electrical and Electronics Engineers Inc. | 16 | 0.00 |
| Engenharia Agricola | journal | 17944 | Sociedade Brasileira de Engenharia Agricola | 33 | 0.94 |
| European Journal of Wildlife Research | journal | 10254 | Springer Verlag | 62 | 1.99 |
| Rudarsko Geolosko Naftni Zbornik | journal | 14286 | Faculty of Mining, Geology and Petroleum Engineering University of Zagreb | 22 | 1.78 |
| Year | Impact Score (IS) |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 2.03 |
| 2023 | 2.06 |
| 2022 | 1.97 |
| 2021 | 2.31 |
| 2020 | 2.77 |
| 2019 | 2.03 |
| 2018 | 1.28 |
| 2017 | 1.98 |
| 2016 | 2.17 |
| 2015 | 2.06 |
| 2014 | 1.78 |
